In a groundbreaking development, Neurocrine Biosciences, Inc. has announced the FDA approval of CRENESSITY™ (crinecerfont), a first-in-class therapy for managing classic congenital adrenal hyperplasia...

New findings from Neurocrine Biosciences showcase the efficacy of CRENESSITY in managing congenital adrenal hyperplasia, highlighting improved hormone regulation in patients.

Neurocrine Biosciences showcased significant one-year data at the 2025 Endocrine Society Meeting, highlighting weight management success in CAH patients treated with CRENESSITY.

Neurocrine Biosciences reveals significant findings from the Phase 3 CAHtalyst™ Pediatric study, showing CRENESSITY™ improves outcomes for CAH patients.

Neurocrine Biosciences has launched CRENESSITY™, a groundbreaking treatment for classic congenital adrenal hyperplasia (CAH), now available in the U.S. for eligible patients.

The recent FDA approval of Crenessity marks a significant advancement in treating congenital adrenal hyperplasia, benefiting patients of all ages.

Neurocrine Biosciences (NASDAQ: NBIX) presented one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) at ENDO 2025. The Phase 3 trial, involving 182 adult patients aged 18-58, demonstrated sustained efficacy in treating classic congenital adrenal hyperplasia (CAH).Key findings include 25-30% reduction in glucocorticoid doses while maintaining or improving androstenedione levels. The study showed improvements in insulin resistance and hirsutism in female participants. CRENESSITY demonstrated a favorable safety profile, with headache and fatigue as the most common side effects, mostly mild to moderate and temporary.The data complements previously reported pediatric results and reinforces CRENESSITY's role in CAH management by effectively controlling ACTH and adrenal steroid imbalances while enabling lower, more physiologic steroid dosing.

Neurocrine Biosciences reported impressive financial results for the fourth quarter and fiscal year 2024, driven by robust sales growth and new product launches. Financial outlook for 2025 looks promising.

Neurocrine Biosciences has received FDA approval for CRENESSITY™, a groundbreaking treatment for Congenital Adrenal Hyperplasia in patients aged four and older. This milestone is a significant advancement for CAH management.

Neurocrine Biosciences is set to present significant findings from its Phase 3 CAHtalyst Pediatric study at the upcoming PES 2025 Annual Meeting, showcasing benefits of CRENESSITY.

Neurocrine Biosciences shares its impressive Q2 2025 financial results, highlighting key sales growth and advancements in its treatment pipeline for neuropsychiatric conditions.

Neurocrine Biosciences has reported impressive financial results for Q3 2025, showcasing significant growth in net product sales, particularly for INGREZZA and CRENESSITY.

Neurocrine Biosciences has chosen PANTHERx® Rare for distributing Crenessity™, an innovative treatment for congenital adrenal hyperplasia affecting many lives.

Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million.

Neurocrine Biosciences has reported robust financial results for the first quarter of 2025, reaffirming its sales guidance and detailing recent developments in its innovative therapies.

Neurocrine Biosciences has published a significant supplement on classic congenital adrenal hyperplasia in a leading medical journal, addressing treatment challenges and innovations.

Neurocrine Biosciences has published a significant review on CAH treatment challenges, proposing novel therapies minimizing glucocorticoid.use.

Neurocrine Biosciences presented compelling one-year data on CRENESSITY at ENDO 2025, showcasing sustained efficacy in treating adults with congenital adrenal hyperplasia.